Format

Send to

Choose Destination
J Clin Oncol. 2019 May 10;37(14):1228-1263. doi: 10.1200/JCO.18.02096. Epub 2019 Apr 1.

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Author information

1
1 City of Hope Cancer Center, Phoenix, AZ.
2
2 International Myeloma Foundation, North Hollywood, CA.
3
3 American Society of Clinical Oncology, Alexandria VA.
4
4 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
5
5 UC San Diego Moores Cancer Center, La Jolla, CA.
6
6 Emory University, Atlanta, GA.
7
7 Mayo Clinic, Rochester MN.
8
8 University of Rochester Medical Center, Rochester, NY.
9
9 National Cancer Institute, Bethesda, MD.
10
10 Juravinski Cancer Center, Hamilton, Ontario, Canada.
11
11 Education and Advocacy, Grand Island, NE.
12
12 Advocate Medical Group, Chicago, IL.
13
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
14
14 Massachusetts General Hospital, Boston, MA.
15
15 Upstate Medical University, Syracuse, NY.
16
16 Hackensack University Medical Center, Hackensack, NJ.
17
17 Georgetown University, Washington, DC.
18
18 McMaster University, Hamilton, Ontario, Canada.
19
19 Central Alabama Radiation Oncology, Montgomery, AL.
20
20 Washington University Medical School, St Louis, MO.
21
21 University of California San Francisco, San Francisco, CA.

Abstract

PURPOSE:

To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others.

METHODS:

ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

RESULTS:

The literature search identified 124 relevant studies to inform the evidence base for this guideline.

RECOMMENDATIONS:

Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.

PMID:
30932732
DOI:
10.1200/JCO.18.02096

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center